BioScrip Commences Patient Enrollment in Teva Neuroscience Therapy Optimization in Multiple Sclerosis (Tops MS) Research Study

BioScrip, Inc. (Nasdaq: BIOS) announced today that Teva Neuroscience tapped BioScrip Specialty Pharmacy as one of several national research study participants in one of the most comprehensive MS research studies announced to date.

TOP MS is a new research study for MS patients. The study will collect information, through online surveys about the quality of life, symptoms, relapse, employment, usual level of activity participation and general health activity from individuals living with MS for a two-year period.

�We are very pleased that BioScrip was selected as a specialty pharmacy study participant�, said Rick Smith, president and COO of BioScrip Inc. �Teva recognized our BioscripCare� MS program�s ability to provide high-quality, comprehensive and personalized MS care on a national basis. At BioScrip, we believe that this study will reaffirm our ongoing commitment to BioscripCare drug therapy adherence programs for patients and physician support services to improve the quality of life for the MS patient.�

�Through the TOP MS study, Teva Neuroscience seeks to enhance our understanding of the issues facing MS patients, further demonstrating our ongoing commitment to the MS community� said MerriKay Oleen-Burkey, project leader, TOP MS Study, Teva Neuroscience. �As one of the nation�s leading specialty pharmacies in MS care, BioScrip�s selection as a partner in the TOP MS study is a recognition of their comprehensive approach to MS therapy management."

The research study will recruit approximately 3,000 participants from several specialty pharmacies nationwide. Individuals should call the BioScrip Specialty Pharmacy Study Coordinator, Kira Botkin at 888-489-744 or by email at TOPMS@bioscrip.com. Following your conversation with Ms. Botkin, you will receive an information packet in the mail which outlines the details of the study.

About BioScrip Inc.

BioScrip, Inc. (www.bioscrip.com) (Nasdaq: BIOS) is a specialty pharmaceutical healthcare organization that partners with patients, physicians, healthcare payors and pharmaceutical manufacturers to provide access to medications and management solutions to optimize outcomes for chronic and other complex health care conditions.

Forward Looking Statements

This press release may contain statements which constitute forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the intent, belief or current expectations of the Company, its directors, or its officers with respect to the future operating performance of the Company and our success with respect to the integration and consolidation. Investors are cautioned that any such forward looking statements are not guarantees of future performance and involve risk and uncertainties, and that actual results may differ materially form those in the forward looking statements as a result of various factors. Important factors that could cause such differences are described in the Company�s periodic filings with the Securities and Exchange Commission.

BioPlus Acquisition (NASDAQ:BIOS)
Graphique Historique de l'Action
De Sept 2024 à Oct 2024